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Abstract
HYPOTHESIS:
The purpose of this retrospective chart review was to quantify the effectiveness
of steroid injections have in treating new trigger fingers in patients with a history of
injection resistant trigger finger.
METHODS:
Forty-three study subjects were defined as those patients who presented with
trigger finger, underwent at least one steroid injection followed by surgical release of
the A1 pulley, and subsequently represented with another trigger finger in a distinct
digit and compared to a group of 40 control subjects presenting with first trigger
fingers. Demographic data, PMH, and treatments for trigger finger were recorded.
Subjects were surveyed to assess any residual symptoms and level of satisfaction with
injection treatment. The control and study groups were then compared by student’s T
test for any statistically significant differences in measured outcomes. Decision Tree
Analysis of cost for treatment of repeat trigger finger was employed using Precision
Tree Software.
RESULTS:
The study group had higher proportion of injection resistant trigger finger than
control group with 49% (21/43) of patients and 38% (35/91) of digits proceeding to
surgery vs 23% (9/31) of patients and 22% (11/38) of digits in the control group (p
values 0.01 and 0.05 respectively). There were no significant differences in number of
injections before surgery or resolution of symptoms, the duration of symptoms before
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first injection or before surgery, patient satisfaction with injection treatment, or patient
willingness for future injection treatment. 87% (26/30) study group digits had complete
resolution of symptoms on survey vs 57% (16/39) digits in the control group (p value
0.011) with the most common side effect being stiffness.
There were no significant differences in gender, age, and medical comorbidites
between the two groups including diabetes. The study group had statistically significant
higher incidence of carpal tunnel syndrome (p value 0.0001), Dupuytren’s disease (p
value 0.026) and occupational exposure (p value 0.012).The distribution of affected
fingers differed with trigger thumbs being more prevalent in the control group (p value
0.0044). Precision Tree Software revealed that injection treatment was a cost efficient
method of treating trigger digits in patients with previous injection resistant trigger
finger.
SUMMARY POINTS:
Patients returning for with a new trigger finger after having required surgery for
another finger can still respond to non operative treatment, specifically a steroid
injection. It is our clinical recommendation that steroid injection treatment should be
considered for initial or repeat presentation of trigger finger.
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Background:
Trigger finger, or stenosing tenosynovitis, is a condition where the normal smooth
gliding of the flexor tendons through the fibrous tendon sheath of the digit is altered.
Inflammation where the flexor tendon enters the sheath leads to either thickening of the
fibrous pulley and/or inflammation or nodular enlargement of the tendon. This
enlargement of the tendon results in locking and clicking symptoms of the affected
finger where the patient is unable to fully extend of flex the finger without the area of
tendon enlargement becoming trapped within the tendon sheath.

Anatomy and Pathobiology of Tenosynovitis
Normal finger flexion is a finely coordinated movement initiated by the flexor
digitorum superficialis and profundus that reside in the palm of the hand. The muscle
belly is connected to the phalanges by a flexor tendon that is guided by a tendon sheath
and complex pulley system composed of eight focal thickenings of the flexor tendon
sheaths. These flexor tendon sheath thickenings are referred to as the five annular
pulleys (A1 thru A5) and the three cruciate pulleys (C1 thru C3) (Figure 1). These
retinacular structures serve two functions: first they maintain the flexor tendon position
relative to the bones and second, they provide a fulcrum to generate increased power of
flexion to prevent bowstringing of the flexor tendon.
The tendon sheath has a membranous, synovial component. The synovial sheath is a
double walled hallow tube containing synovial fluid through which the flexor tendon
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travels that extends proximally to the carpal tunnel in digits I and V, and to the MP joint
in digits II, III, and IV (1).
Some controversy exists in the literature regarding the precise histology of the normal
A1 pulleys and the histology of trigger finger affected pulleys (2) (3) (4) (5).
Sbernardori and Bandiera compared sections of the central portion of 40 A1 pulleys
from adult patients with symptoms of trigger finger from sections from 10 healthy
volunteers were subjected to light and electron microscopy to study the histology and
ultrastructural make up of the samples (6). They showed differences in the connective
tissue structure of the normal A1 pulleys vs pathologic ones. Normal pulleys consist of
two distinct connective tissue layers, an inner layer of organized collagen bundles with
occasional fibrocytes and scant extracellular matrix, and an outer layer of loosely
organized collagen (shown in Figure 2).
They found in the pulleys of triggering digits, there were three distinct histologic layers.
There was an additional inner layer (labeled c in figure 3) that was not present in the
normal samples consisting of irregularly organized collagen with more extracellular
matrix, with round cells organized lacunae and islands of chondroid metaplasia. The
other two layers were as described for the normal pulleys. The underlying flexor
tendons exhibit a nodular or fusiform swelling and with granulation tissue—both
believed to be secondary to stenosis caused by the thickened tendon sheath.
Chondroid metaplasia, is the formation of cartilage-like cells in tissues where they are
not normally found. Beyond trigger fingers, this finding has also been described as part
of a degenerative process that takes place in the rotator cuff supraspinatus tendon (7)
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and in the ACL (8). Several cell lines are capable of differentiating into chondroid–like
structures including fibrocytes (9), tenocytes (10), and synoviocytes (11).
Several studies have characterized stimuli that are associated with chondroid metaplasia
in tendons. Giori et al found that the level of compressive and hydrostatic forces on
tendons correlated with the degree of fibrocartilaginous metaplasia (12). The tissuelevel mechanical stimuli associated with forces where tendons and ligaments had to
cross bony or fibrous pulleys appeared to regulate cartilaginous and fibrous matrix
composition of connective tissues.
The presence of chondroid metaplasia and its association with abnormal mechanical
stimuli could indicate that the pulley thickening associated with trigger finger is related
to an increase of pressure in the A1 pulley as a result of abnormal frictional forces
developed during digital flexion. These forces could precipitate differentiation of
fibrocytes or other stem cells located in the visceral layer of the pulley towards
chondrocyte like cells and fibrocartilaginous metaplasia. Based on its anatomic location,
the A1 pulley, may be particularly stressed during digital motion.

Clinical Presentation and Evaluation
The classic clinical history of flexor tendon entrapment usually refers to a slow onset of
pain symptoms that occur more frequently over time. During this “pretrigger” phase,
pain is worsened by exercise or hand-use intensive labor. Stage II, the “active stage”,
refers to objective presence of clicking of the symptomatic finger which the patient is
able to overcome by actively extending the finger. This stage progresses to stage III or
the “passive” stage during which the patient cannot actively overcome the discrepancy
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between tendon and flexor sheath diameter. As a result, the patient must manually
extend the finger by forcing it to straighten with the asymptomatic hand (stage IIIA) or
the patient is unable flex the finger (stage IIIB). The final stage IV, is the presence of
rigidity of the finger in a flexion posture (13). These findings are confirmed on physical
examination (Table 1).

Treatment Options
Treatments for trigger finger in order of invasiveness include splinting, NSAIDs,
physical therapy, corticosteroid injections, and surgical release of the tendon sheath.
There are no level 1 or level 2 studies that assess the effectiveness of exercise, physical
therapy, splinting, or treatment with non-steroidal anti-inflammatory medication in the
orthopaedic literature.

Physical Therapy, Exercise, and Splinting
There are no trials assessing exercise, stretching, mobilization, and hot or cold
modalities. However there are some studies that assess splinting as a modality for the
treatment of trigger fingers. The goal of splinting is to alter flexor tendon biomechanics
to minimize force over the affected joint while maximizing tendon glide (14). At this
point there is no agreement in the literature as to which joint to include in the splint and
the degree of joint positioning. There have been no trials comparing different joint
splint strategies and there are no standardized protocols for splinting.
Colbourn et al. evaluated the efficacy of custom thermoplastic splinting in 28 patients
(14). Patients wore a low-profile custom thermoplastic MCP blocking (ring) splint for
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six weeks and pre and post outcomes measured. After the use of a splint, there were
statistically significant improvements in the stenosing tenosynovitis grade, numeric pain
rating scale, the number of triggering events in ten active fists, and in the participant
perceived improvement in symptoms. Grip strength did not significantly change.
However, it is impossible to gage the significance of these effects without a control
group.
Another prospective study in 21 manual workers assessed splinting of the DIP joint
(15). Splinting was the primary intervention, and a single corticosteroid injection was
offered if triggering was stage 4 or greater. After mean follow up of one year, 81% of
digits (50% of patients) were treated successfully. This study also lacked a control
group.
A third study of 50 patients assessed splinting of the MCP joint at 10-15 degrees of
flexion for an average of 6 weeks (range 3-9 weeks) (16). In this protocol, the DIP and
PIP joints were free to move. Outcomes of the splinted subjects were compared to
another 50 patients who received a corticosteroid injection. Treatment was successful in
66% of splint treated patients as compared to 84% of injection treated patients.

/on-Steroidal Anti-Inflammatory Medication
Non-steroidal anti-inflammatory medications can be used in the treatment of trigger
finger for pain control (17). There are no trials in the English literature showing the
effectiveness of non-steroidal anti-inflammatory medications in the treatment of trigger
finger symptoms such as triggering or locking.
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Steroid Injections
Injections with corticosteroids are the most commonly used treatment for trigger finger
(18) and were described as early as 1953 (19). The goal is to place the medication
directly into the flexor tendon sheath, though injection in proximity of the sheath has
also been shown to be effective (20) (21). Common medication combinations used
include 0.5 ml of the steroid dexamethasone (4 mg/ml) combined with 0.5 ml of 1%
plain lidocaine or .5 ml of triamcinolone with 0.5 ml lidocaine mixed in a 3 cc syringe,
utilizing a 5/8 no 27 needle (22) or 1.0 mL betamethasone, 0.5 mL of 1% plain
lidocaine and 0.5 mL of 0.5% bupivicane.
Injection treatment for trigger finger has been shown to be effective in 67% (23) to 93%
(24) for anywhere from 1-4 injections per finger. A recent double blind randomized
placebo controlled trial comparing saline placebo injection with 1 mL
triamcinolonacetonide (TCA) in a total of 50 patient (25 in each group) showed that
patients in the TCA group had a higher rate of immediate symptom improvement than
in the control group 16/25 vs 5/25 (p value 0.001) and improvement in triggering 13/24
vs 5/22 (p value 0.053) (25). While this is the first randomized controlled study
comparing corticosteroid treatment to placebo, it suffers from low subject enrollment.
There are two approaches to injection treatment for trigger finger. The conventional
technique involves direct injections into the flexor tendon over the metacarpal head.
This technique is associated with significant pain. In 1984, Carlson and Curtis described
an alternative, midaxial technique that reportedly might minimize patient discomfort
(26). In this technique the needle is pushed to the bone at the proximal phalange level
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and then adjusted so that the head of the needle enters the flexor tendon sheath. The
surgeon will know that they have successfully entered the tendon sheath as the
medication should be easily injected. Two studies have compared the conventional
technique (CI) and midaxial technique (MAI). In an abstract presented at the ASSH by
Bernstein RA, MAI and CI were compared in an RCT in 115 subjects where success
rates in resolving triggering symptoms were 72% and 73% for CI and MAI respectively
(p value > 0.05, non-significant) (27). Patients also quantified their pain using a Visual
Analog Pain scale and there was no statistically significant difference on whether one
approach was more painful.
A second study comparing the two techniques quantified pain by Visual Analog Pain
Scores (VAS) and found scores of 40.19 ± 23.3 and 48.39 ± 26.5 for the MAI and CI
technique groups, respectively (28). These scores were not statistically significant by
students T-test. The authors also conducted a Pearson’s chi squared assay. The authors
categorized patients into groups with pain scores ≥50 and pain scores <50. The chi
squared test was statistically significant (p value < 0.05), however, it is unclear whether
these categories are clinically significant, especially given the large spread of data
(approximated by the standard deviations), non-significance of the student’s T test, and
arbitrariness of the category distinction given that the VAS score is a continuous
variable.
Traditionally, physicians attempt to inject steroid medication within the synovial sheath,
the goal being to provide the highest concentration of medication possible to the area of
pathology. Intrasheath injections however do come with additional risk of damage to
the flexor tendon. The effectiveness of intrasynovial vs extrasynovial injection was first
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assayed by Taras et al assessed the injection location with radiopaque dye (20). In a
prospective trial, Taras et al found those subjects who had intrasheath injections had a
47% resolution of triggering, those who received medication both in the subcutaneous
tissues and intrasheath (due to leak as tracked with the radiopaque dye) had 50%
resolution of symptoms, and those who had subcutaneous injection had 70% resolution
of symptoms. The authors concluded that there was no benefit to intrasheath injection
compared to subcutaneous injection.
The relative benefit of intrasheath injections was revisted by Kazuki et al in a
prospective cohort of 100 patients with triggering symptoms graded into three classes of
severity (grades I-III in order of increasing severity). There was no control or placebo
group. They found that pain was relieved in 98% of the cases and triggering relieved in
74% of cases (21).
The most common side effects of steroid injection for trigger finger are steroid pain
flare and skin blanching at the site of injection. The steroid pain flare is an increase in
pain after the initial injection and is thought to be caused by the crystallization of
steroid crystals leading to a transient increase in pain that resolves over time (29).
Other side effects include infection and a transient increase in blood sugar in patients
with diabetes. The increase in blood sugar in diabetics can be marked, especially the
first morning after injection where one study showed an average increase in blood sugar
of 73% above average preinjection levels. The increase in blood sugar can last at least
five days, with an average increase in blood sugar of 26% above preinjection levels at
day five (30). A review of the literature reveals case reports of rarer side effects such as
necrotizing fasciitis (31), multiple pulley rupture (32), delayed flexor digitorum
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superficialis and profundus tendon rupture (33), and shower emboli with associated
digital necrosis (34) can be associated with trigger finger steroid injection.
Rozental et al prospectively followed a cohort of 130 patients with primary presenting
trigger fingers to quantify prognostic factors associated with symptom recurrence
including patient demographics, comorbidities, and aspects of their symptom
presentation (35). They found that insulin dependent diabetes mellitus was a strong
predictor of symptom recurrence (p <0.01). Independent predictors of surgical release
included younger age (p < 0.01), multiple symptomatic digits upon initial presentation
(p < 0.01), and history of other upper extremity tendinopathies (p = 0.02). Interestingly
duration and severity of symptoms were not for predictors surgical release. This group
also performed Kaplan-Meir analysis to follow the symptom-free duration following
injection treatment. Ultimately 56% of the digits followed in their cohort had a
recurrence of symptoms within one year following injection treatment.
Injection resistance in patients with diabetes was studied in a prospective, double
blinded RCT where cohorts of thirty diabetic patients and twenty nine control patients
were randomized to receive either placebo or corticosteroid injections; success was
defined as resolution of symptoms such that surgical intervention was not required (36).
Consistent with the Roznetal study, diabetic patients were found to have a lower success
rate than non diabetic patients (p value 0.03). Interestingly, within the diabetic group,
corticosteroids did not decrease the surgery rate significantly over placebo, however, as
there were only 30 patients in the diabetes group, this study may have been
underpowered to show non-significance.
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Associated Hand Co-morbidities of Trigger Finger
Both trigger finger and carpal tunnel syndrome are associated with medical conditions
such as diabetes mellitus, rheumatoid arthritis, and hypothyroidism. Kumar and
Chakrabarti prospectively followed a group of 551 patients who did not have diabetes,
RA, or hypothyroidism to determine if there was any independent association of carpal
tunnel syndrome with trigger finger (37). Kumar and Chakrabarti found that 43% of
patients with trigger finger also had carpal tunnel syndrome, and 21% of the patients
with carpal tunnel syndrome also had trigger finger. This study was repeated by
Rottgers et al who found a similar association between trigger finger and carpal tunnel
syndrome (38). Rottgers et al also concluded that because of the high rate of
comorbidity between the two conditions, patients that present with trigger finger should
also be evaluated for carpal tunnel syndrome and vice versa.

Economic Considerations and Cost Effectiveness
Two studies have looked the costs associated with trigger finger treatment. In a study
from the UK, Webb and Stothard (39) conducted a prospective, cost-minimization study
on patients who presented with common hand conditions such as trigger finger,
Dupuytren’s disease, and hand ganglions. Each patient who presented to their clinic
with injection resistant trigger finger was offered percutaneous release. Only those who
failed two attempts at percutaneous release were then offered open surgical release;
there were no exclusion criteria. All variable costs associated with the procedures
including operating room and out-patient room time, basic consumables, nursing and
anesthesia staffing. Medical personnel staff costs were considered fixed costs and were
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excluded from analysis. Over the six month time period, 52 patients presented with
trigger fingers, of which 44/52 (85%) were successfully treated as an outpatient with
percutaneous procedure, and the remaining 8/52 (15%) were treated surgically. Cost
savings for trigger finger treated in the outpatient setting vs in the operating room was
609₤ (15₤ outpatient vs 624₤ surgical) resulting in 609₤ greater net income for the
provider based on a national tariff income of 1322₤ for trigger finger (Figure 4).
Cost effectiveness of trigger finger treatment has also been studied in the American
healthcare system (40). Kerrigan and Stanwix examined five strategies for treating
trigger fingers including different combinations of injection, surgery, and percutaneous
release seeking to identify the least costly algorithm.
Using decision tree analysis (DATA, TreeAge Software Inc), the five strategies were
used to construct a five branched decision tree. Success in the decision tree was defined
at no need for additional treatment within 8.0 weeks to 8.5 years (depending on the
study), whereas failure was defined as necessitating additional intervention or lack of
relief of symptoms. Success rates for the decision tree were calculated from existing
literature, using the median success rate from all published trials for a given
intervention. The treatment strategies assayed were 1) 1 steroid injection followed by
surgical release for failures (steroid option 1), 2) 1 steroid injection followed by a
second injection for failures followed by definitive surgery if needed (steroid option 2),
3) same as 2) with a third steroid injections before definitive surgery for failures (steroid
option 3), 4) surgical release, and 5) percutaneous release with definitive surgery for
failures. The decision tree is shown in Figure 5.
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The authors found that Steroid option #2 (one steroid injection followed by a second
injection for failures followed by definitive surgery if needed) was the most cost
effective option for treatment of trigger finger. On average, surgery cost payers (such as
private insurance companies and Medicare) between 248% and 340% more than the
steroid option #2. This option represents the least costly of acceptable treatment
algorithms for the treatment of trigger finger.
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Statement of Purpose & Hypothesis:
The goal of this study is to quantify the level of effectiveness steroid injections have in
treating new trigger fingers in patients with a history of injection resistant trigger
fingers. Thus the hypothesis is: If steroid injections are as effective in treating trigger
finger symptoms in patients with previous injection resistant trigger finger as they are in
primary fingers, then symptom recurrence rates should be equal in a sample of patients
with primary trigger fingers as in a sample of patients with second trigger fingers who
needed surgery for previous symptoms.

Clinical Significance:
There are currently no studies that address the efficacy of steroid injection treatments in
those patients who have previously failed trigger finger injection treatment. As outlined
in Kerrigan and Stanwix, there are multiple treatment algorithms for treatment of trigger
fingers ranging from proceeding directly to surgery to up to three injections before
considering surgery (40). There are no best practice guidelines published as of the date
of this review. Given the potential heterogeneity of treatment algorithms of primary
trigger fingers, one might assume there is also heterogeneity in the treatment of those
patients presenting with secondary trigger fingers, especially in those patients who have
previously had injection resistant fingers. Some orthopaedic surgeons might opt to
proceed directly to surgical treatment given that the patient has in the past not
responded to injections, the injections are painful (28), the patient may have a relapse of
triggering symptoms (35), and surgery is relatively safe and the definitive treatment.
However, the surgery is not without risks.
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A recent chart review documented the rates of both major and minor complications in a
cohort of 43 patients who underwent 78 open releases of A1 pulleys for trigger finger
(41). The found a major complication rate (i.e. complications that required further
surgery) of 3% (2/78) and a minor complication rate (i.e. complications that resolved
with non-operative treatment or did not reduce function) of 31% (24/78). The major
complications included a synovial fistula that required excision and proximal
interphalangeal joint arthofibrosis which caused pain. Minor complications included
decreased range of motion, scar tenderness, pain, and wound erythema. The authors
noted that the rate of minor complications was surprisingly high.
The ultimate goal is to provide the patients with effective treatment for their trigger
finger condition while minimizing risk. Given the potential for both major and minor
complications during open pulley release for trigger finger, our study hypothesis sought
to determine whether trial of injection treatment should be attempted in a population of
patient who had previously failed injection treatment. Steroid injection is a less invasive
procedure than open release of the A1 pulley and carries a lower rate of complications.
At the same time, if injections were ineffective in a population of those patients who
have previously failed injection treatment and required surgery, then patient suffering
would be prolonged if they were subjected to a trial of steroid injections.
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Methods:
Trigger Finger Sample
One hundred sixty three patients who presented to the study sponsor’s practice between
the years of 1999 and 2008 were identified as potential candidates for the chart review
by CPT code search for code 26055 - Tendon Sheath Incision (eg, for trigger finger)).
Of these 143 original patients, a subset of 43 patients with a history of at least one
episode of injection resistant trigger finger treated surgically that subsequently
developed a second trigger finger treated was identified. Exclusion criteria were
presence of rheumatologic disease or previous treatment with steroid injection.
Participants ranged in age from 40 to 84 years at the time of presentation of their index
case trigger finger (average age at index case presentation 58.8 years). The gender
distribution between males and females was biased towards females who made up 70%
of the sample (30 females, 13 males).
Additional descriptive data collected included past medical history of diabetes,
hypothyroidism, or OA, non-injection and non-surgical treatment of trigger finger,
BMI, history of other upper extremity orthopedic conditions, and treatment for upper
extremity orthopedic conditions.

Control Sample
The comparison sample consisted of 56 consecutive patients presenting with primary
trigger fingers treated with injection between the dates of 3/1/08 and 6/1/08. Exclusion
criteria were presence of rheumatologic disease, previous treatment with steroid
injection or surgery for trigger finger. Of the 56 consecutive patients, 40 met eligibility
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requirements for the study. These participants ranged in age from 44 to 81 years of age
(average 65 years at time of presentation of index case trigger finger). The gender
distribution between males and females was biased towards females who made up 65%
of the sample (26 females, 14 males). Additional descriptive data was collected as
described for the study group.

Procedure
The charts of the 83 adults (43 study patients and 40 controls) were reviewed and data
obtained regarding their past medical history relevant to trigger finger (presence of
diabetes, insulin treatment for diabetes, hypothyroidism, or gout), demographics (age at
presentation, BMI, sex, and occupational exposure), as well as the presence of any other
upper extremity pathology and associated treatment for the upper extremity pathology.
The subjects were then consented as described in Yale HIC # 0912006039 and surveyed
by phone using form 1 shown in the Appendix.
The control and study groups were compared on all metrics including demographic
information trigger finger characteristics, incidence of treatments including injection
and surgery, and survey data. A student’s T-test was used to assay the significance of
differences between the two groups. A P-value of less than or equal to 0.05 was
considered statistically significant. Success of the corticosteroid injection was defined
as the absence of triggering symptoms at 12 month followup.
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Results:
Demographics and Trigger Finger Characteristics
There were no differences in gender distribution and BMI between the two groups (p
values of 0.65 and 0.46 respectively). However, there was increased incidence of
occupational exposure in the study group where the control group subjects had 15%
(6/40) prevalence of occupation exposure (as reported by the patient as either
workman’s compensation or hand-intensive occupation or hobby) and while the study
group had 40% (17/43) prevalence (p value 0.01). There were no differences in the
prevalence of other medical comorbidities including diabetes (p value 0.95), diabetes
treated with insulin (p value 0.96), hypothyroidism (p value 0.59), and gout (p value
0.96). There was no difference between the two groups in the incidence of hand
osteoarthritis, as diagnosed radiographically (p value 0.36).
Factors characterizing the trigger finger were tracked. The forty patients in the control
ultimately presented with forty-nine affected fingers (average 1.23 fingers per patients,
range 1 to 3 fingers). The forty-three patients in the study group presented with ninetyone fingers (average 2.12 fingers per patient, range 1 to 6). Right hands were affected
73% (28/49 fingers) of the time in the control group and 54% (49/91 fingers) of the time
in the study group (p value 0.11). Dominant hands were affected nearly twice as often
in the control group than the study group 73% vs 42% though with the numbers
available this was not statistically significant (p value 0.08).
The distribution of fingers affected also differed between the control group and the
study group. Trigger thumbs were more prevalent in the control group with 41% (20/49)
of digits affected as opposed to 19% (14/91) in the study group (p value 0.0044). There
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was a statistically significant higher prevalence of index fingers in the study group as
well with 15% (14/91) fingers affected as opposed to 4% (2/49) in the control group (p
value 0.045). Overall, the distribution of trigger digits was more even in the study group
as opposed to the control group where the majority of digits affected were thumbs,
third, and fourth digits.

Hand Co-morbidities
As described previously, several hand conditions have been associated with trigger
finger. Seven of the most common upper extremity conditions were tracked for
comparison. Statistically significant differences between the study and control groups
were found in the prevalence of carpal tunnel syndrome and Dupuytren’s disease (p
values 0.0001 and 0.026 respectively). Prevalence levels of other hand conditions such
as the presence of cysts, Dequervain’s tenosynovitis, RSI, shoulder impingement, and
epicondylitis were not statistically different (p values ranging from 0.59 to 1.00).
Levels of treatment for other hand morbidities ranged from non-operative interventions
such as splints, physical therapy, injections, and NSAIDs, as well as surgical procedures
were not statistically different between the control and study groups (p values ranging
from 0.1 to 0.64).

Survey Data
Patients were surveyed by telephone to 1) determine if patients had any treatments for
trigger finger besides those documented in the patient’s charts and 2) to quantify the
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residual symptoms and relative satisfaction the patient had with injection treatment for
trigger finger. Eighty percent (32/40) of control group patients were available for
followup vs only 56% (24/43) of study group patients (p value 0.019). This was likely
due to the fact that many study patients were several years out from their last visit for
trigger finger and their contact information was not updated. No patients in either the
control group or the study group had either injection treatment or surgery for trigger
finger at any facility outside of RAB’s practice.
Patients were also surveyed regarding any residual symptoms after either injection
treatment or surgery. Final followup was defined as the time elapsed from the last
injection treatment to the date of survey and was 44.75 months (range 3.53-112.73) for
the study group and final follow-up 16.3 months (range 5.0-21.3) for the control group.
The most common symptom after injection treatment was stiffness in 32% (9/28)
control subjects and 0% (0/24) study subjects (p value 0.011). Pain was the second most
common symptom in 11% (3/28) control group subjects and 10% (3/30) in the study
group. No patients in either group who had injection treatment were experiencing any
clicking or locking at followup. 91% (21/23) of patients in the control group were
satisfied with injection treatment for trigger finger vs 83% (10/11) in the study group (p
value 0.5). Ninety one percent (21/23) of patients in the control group would be willing
to undergo injection treatment for trigger finger again vs 83% (10/11) in the study group
(p value 0.5).
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Injection Efficacy and Surgery Rates
We assayed whether longer duration of trigger finger symptoms before injection
treatment with increased nonoperative treatment failure rates. Tables 6a, 6b, and 6c
compare the duration of symptoms before first injection and duration of symptoms
before surgery to see if there was any difference. Table 6a compares patients in the
control group who either required to surgery or those who did not. The average time
between onset of triggering symptoms before first injection was 15.45 weeks in those
who had surgery for trigger finger vs. 16.08 weeks for those control group patients who
did not need surgery for their symptoms (p value 0.94). Time till surgery was 58.06
weeks for the control + surgery group.
Table 6b illustrates the same analysis for the study group. In patients in the study group
who went onto have surgery for their triggering symptoms there was 15.20 week
duration before first injection vs. 12.93 weeks for those study group patient who did not
need surgery (p value 0.56). Time from onset of symptoms to surgery was 101.74
weeks for the study group.
Table 6c compares the control group with the study group. Among those patients who
had surgery, the control group averaged 15.45 weeks and the study group averaged
15.20 weeks before first injection (p value 0.97). The control group averaged 58.06
weeks of symptoms before surgery vs. 101.74 weeks for the study group (p value
0.073). Among those who did not need surgery for their triggering symptoms, the study
group had on average 16.08 weeks symptoms before first injection and the study group
averaged 12.93 weeks (p value 0.55).
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The absolute prevalence of surgical treatment in the control and study groups was
compared. There were 23% (9/40) control group patients who needed surgery for their
symptoms vs. 49% (21/43) of patients in the study group (p value 0.01). Among digits,
22% (11/49) of digits in the control group needed surgery vs. 38% (35/91) in the study
group (p value 0.05).

Effect of Diabetes
In Rozental et al, diabetes was found to be independently correlated with inferior
outcomes of corticosteroid injection treatment (35). Table 9 shows the surgery rates for
the diabetic and non-diabetic patients in both the control and study groups. In our
sample groups, 25% (10/40) control group and 26% (11/43) study group had diabetes
with 2.5% (1/40) insulin dependent diabetics in the control group and 2.3% (1/43)
insulin dependent diabetics in the study group. There were no significant differences in
the rates of surgery when comparing diabetic to non-diabetic patients, and when
comparing control and study groups (p values ranging 0.30-0.94).

Multiple Presenting Fingers vs. Single Presenting Fingers
In Rozental et al, patients who presented with multiple trigger fingers had higher rates
of corticosteroid injection treatment failure than those patients who presented with a
single symptomatic finger (35). Table 10 shows the surgery rates for those who
presented with multiple and single digits in both the control and study groups. Contrary
to Rozental’s study, there were no significant differences in the rates of surgery when
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comparing multiple finger presenting and single finger presenting patients, and when
comparing control and study groups (p values ranging 0.15-0.96).

Decision Tree Analysis
A decision tree analysis using Precision Tree Software© (Palisade Decision Tools) was
performed using reimbursement values from Medicare obtained from Kerrigan et al of
$171 for corticosteroid injection and $1227 for open release of flexor tendon for trigger
finger (40). These direct costs included professional fees (those fees paid to the
orthopaedic surgeon and anesthesiologist) and technical fees (incidental hospital costs,
medications, supplies, nursing costs and equipment). Indirect costs were not considered
(opportunity cost of time, QALY, etc). There were four treatment arms in our analysis
for patients with previous injection resistant trigger finger requiring surgery
representing with a new and distinct trigger finger: 1) Default directly to surgery, 2)
One injection, if failure then surgery, 3) Two injections, if failure then surgery, 4) Three
injections, if failure then surgery. Probabilities for the success of each arm were taken
from the chart review data in this study. The decision tree was constructed and we
found that with a success rate of 36.67% in our data set, three corticosteroid injections
followed by surgery had the least economic impact at an average cost of $678.43. Three
branch decision analysis shown in Figure 9 analyzes the economic impact of 1) Default
directly to surgery, 2) One injection, if failure then surgery, 3) Two injections, if failure
then surgery. The total value of the decision was $791.12 with the injection strategy of
2 injections followed by surgery being the decision with the least economic impact.
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Discussion:
Stenosing tenosynovitis is a disease where there is gradual growth of a fibrous tissue
over the flexor tendon of a finger or thumb that eventually leads to a relative narrowing
of the flexor tendon sheath. This leads to friction between the thickened flexor tendon
nodule and the connective tissue pulleys leading to pain, restricted movement, and the
characteristic triggering or “popping” symptoms associated with trigger finger. A
commonly accepted treatment protocol for primary presenting trigger finger is a trial of
up to two corticosteroid injections into the tendon sheath followed by surgical release of
the restrictive pulley if non-operative treatment is not successful. At this point, there are
no studies addressing treatment protocols for those patients with a history of injection
resistant trigger finger who present with new, distinct trigger. The hypothesis for this
study originated when patients asked the study’s sponsor, “because surgery was needed
for another finger, will cortisone work for the new finger?”
The primary goal of the study was to determine the relative success rate of
corticosteroid injections in our study population as compared to a control population of
patient presenting with primary trigger fingers. As shown in Table 7, there was a
statistically significant difference in the surgery rates where 49% (21/43) of study
patients, 38% (35/91) of study digits had surgery (and thus failed non-operative, steroid
injection therapy). This is compared with control group surgery rates of 23% (9/40)
patients and 22% (11/49) digits (p values of 0.01 and 0.05 respectively). Patients in the
study group had higher rates of surgery than those patients in the control group who
were presenting with their first or primary finger. This result is significant for
counseling patients who return with multiple trigger fingers in distinct digits after
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having surgery for previous trigger finger as in this cohort, 51% of patients avoided
surgery by using the less invasive injection treatment.
Long term follow up by telephone survey of those patients who underwent successful
injection treatment found that the vast majority of both control group and study group
patients were satisfied with injection treatment and would have the treatment again if
needed. No patients underwent trigger finger treatment outside the study practice. The
average follow up for the control group was significantly less than for the study group
(average 16.03 months, range 5.0-21.3 for the control group vs 44.75 months, range
3.53-112.73 for the study group). The reason for this discrepancy was because the study
group was gleamed from the entire duration of the sponsor’s practice while the control
group was obtained from a group of 50 consecutive patients who presented during a
randomly chosen period of 3/2008-6/2008.
There was a statistically significant higher incidence of stiffness as a residual symptom
after corticosteroid injection in the control group than in the study group in the
telephone survey. Patients with 9/39 digits surveyed in the control group reported
symptoms of stiffness vs. patients with 0/55 digits surveyed in the study group (p value
0.0005). This may be because all patients in the study group had surgery and injection
treatments as well as a higher prevalence of hand pathology in general and thus have a
different baseline for stiffness than the control group. Study group patients may be less
likely to report mild symptoms of stiffness due to their higher baseline of pathology.
A secondary goal of the study was to determine characteristics of the study group that
were distinct from a group of patients presenting with first trigger fingers (the control
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group). Demographics analysis revealed that age, gender ratio, BMI, past medical
history (including diabetes, hypothyroidism, and gout) were not significantly different
between the control and study groups. Occupational exposure including hobbies was
significantly higher in the study group than the control group (40% study group vs 15%
control group, p value 0.0012). In addition to higher rates of occupational exposure,
there were higher rates of carpal tunnel syndrome and dupuytren’s contracture (p values
0.0001 and 0.026 respectively). The study group had a 44% incidence of carpal tunnel
syndrome which when compared to the general population incidence of carpal tunnel
syndrome is 0.1-0.3% per year with prevalence of approximately 0.5% (42). The high
rates of carpal tunnel syndrome in our study group, consistent with previous studies (37)
(38), underscores the need for patients with trigger finger to be concomitantly evaluated
for carpal tunnel syndrome. The higher incidence of occupational exposure may the
study group had a higher incidence of more diffuse hand pathology than the control
group.
Interestingly, the distribution of triggering digits differed in the control and study
groups. The dominant hand was more often affected in the control group (73% of the
digits affected were from the dominant hand) while there was a more even distribution
of triggering digits in the study group (only 42% of the digits affected were from the
dominant hand); however this trend only approached significance with a p value of
0.083). The thumb was most often affected in the control group (41% of the time),
while there was a more even distribution of affected digits in the study group. Together
with the higher incidence of diffuse hand pathology, the distribution of affected digits
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may indicate that there is an underlying predisposition to hand pathology rather than
distinct overuse of a particular digit such as the thumb.
Rozental et al showed that insulin dependent diabetes mellitus and presentation with
multiple fingers were independent predictors of non-operative management failure (35).
On the contrary, our sample did not show any association with of comorbidity with
diabetes or multiple fingers at first presentation with surgery rates. This could be due to
sampling error as our samples were smaller than the cohort in the Rozental study.
Consistent with the Rozental study, our samples did not show an association of duration
of symptoms to first corticosteroid injection with surgical intervention.
The economic viability of treatment protocol options was explored in the framework of
Kerrigan et al’s study (40). Two decision tree analyses were performed, one including
all data including those patients who against medical advice received opted to receive
three corticosteroid injections in a single finger, and a second decision tree which only
analyzed those patients that received either one or two injections, or surgery. Both
decision trees showed that it was cost effective to proceed with three or two
(respectively) injections rather than proceeding directly to surgery in those patients who
had previously failed non-operative treatment for trigger finger. Sensitivity analysis
revealed that the reimbursement rate of trigger finger surgery would have to fall below
$678.43 in the case of three injections or below $791.12 in the case of two injections in
order to favor surgery earlier in the treatment protocol.
There only a handful of studies as reported in Kerrigan et al have ever reported success
rates of three corticosteroid injections for trigger finger, and there are no reports of the
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success rates in patients with previous injection resistant trigger finger. Based on the
limited data associated with three rounds of steroid injection for trigger finger, it is
safest to follow the conventional trigger finger treatment protocol of a trial of up to two
steroid injections followed by surgery if non-operative treatment fails for patients with a
history of injection resistant trigger finger who present with new and distinct trigger
digit(s).

Study Shortcomings and Future Directions:
The basic design of this study was a retrospective chart review that is considered a level
3 study. While the results of this study provide the first evidence to support the use of
corticosteroid injections in patients who have had previous injection resistant trigger
finger, it cannot be the basis on which clinical recommendations are made. Clinical
recommendations are made based prospective, level 1 and level 2 clinical trials and
cohort studies.
One reason a retrospective chart review was chosen as an initial study was as an initial
assay of the efficacy of steroid injections in patients with previous injection resistant
trigger finger was because of the relative rarity of the condition and clinical scenario.
As outlined in the results of this study, of the many patients who presented to RAB’s
practice with primary trigger fingers over 10 years, only 143 patients needed open
surgical intervention for their triggering symptoms after steroid injection treatment. Of
those 143 patients who had surgery, only 43 patients returned after their surgeries with
another distinct trigger digit. A prospective trial recruiting patients presenting with first
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primary trigger digits would likely need to enroll 1000 patients in order to get a
sufficient number of patient who proceed to surgery for their triggering symptoms, and
then enough patients to return from surgery with another distinct finger to conduct a
sufficiently powered analysis of the efficacy of steroid injections. A prospective trial of
corticosteroid injections conducted in this fashion, or another similar prospective study
would be necessary to establish firm clinical guidelines or recommendation for the use
of steroid injections in these patients.
One potential shortcoming of the chart review conducted in this thesis was the lack of
use of a standardized outcome measure to provide a validated meaure of the patient’s
subjective impression of the level of function and disability associated with their trigger
digit(s) after injection treatment. The use of the DASH inventory was considered during
the initial study design but was included not as the DASH has questions pertaining to
the entire upper extremity and may not be sensitive enough to show subtle changes in
the function of a single finger. The minimum difference in DASH inventory score
necessary to show a clinically significant difference in outcome is 10 points and there
may not be enough questions that pertain to finger specific function to be detected by
the DASH. Another possible inventory that could be considered would be the Michigan
Hand Outcomes Questionnaire. Given the low rates of finger complications and
disability associated with injection, the phone survey was optimized to minimize
confusion and focus on general satisfaction with treatment, our definition of “success”
of injection treatment (+/- triggering), and rate of surgery. Should there be a prospective
study looking at success rates of injections in this population with in-office visits, then
an outcomes assessment should be used.
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Finally, the cost analysis done in this study took into only took into account the direct
costs associated with the treatment of trigger finger. In the pay-for-service model of
healthcare that is present in the US, the direct costs to the third party payers such as
insurance companies associated with trigger finger treatment can be approximated by
the reimbursement rate for the CPT codes for injection into tendon or sheath and the
code for open release of pulley for trigger finger. Ideally, a thorough costs analysis
study would include other, indirect costs associated with treatment such as post
operative care (revision surgery, rehabilitation, palliative and/or pharmacologic pain
relief), the opportunity costs of the patient’s time that might be spent more productively
at work and the impact the condition and/or the treatment have on the patient’s life. The
latter, the impact the condition and/or treatment have on the patient’s life can be
approximated by the Quality Adjusted Life Year (QALY) which is a measure of disease
burden and can be used as an outcomes measure.
Currently there are no models for QALY or accepted rates of complication associated
with corticosteroid injections for trigger finger and only one retrospective chart review
characterizing the complication rates of open surgical release for trigger finger (41).
Given the lack of evidence characterizing complication rates and the subjective nature
of determining QALYs for conditions such as trigger finger, the decision tree analysis
in this study was limited to direct costs, approximated by the Medicare reimbursement
rates published in Kerrigan and Stanwix (40).
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Conclusions:
There are no published studies examining the responsiveness of trigger finger in
patients with previous injection-resistant tenosynovitis in the English literature. Our
study demonstrates that corticosteroid injections are effective in relieving the symptoms
of triggering in 51% of patients and 62% of digits in our sample with previous injection
resistant trigger finger presenting with symptoms in a distinct finger. Patients with
injection resitant trigger finger have a higher rate of comorbidity with carpal tunnel
syndrome and Dupuytren’s contracture. Additionally, it is cost effective to follow a
treatment strategy of a trial of two corticosteroid injections followed by surgery as
opposed to proceeding directly to surgery. It is our clinical recommendation that a trial
of up to two corticosteroid injections should considered for patients with a history of
injection resistant trigger finger presenting with new and distict idiopathic tenosynovitis
of the thumb and finger.
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Figure 1: Anatomy of flexor tendon showing the intricate pulley system that guides finger
flexion. The pulley most often affected in trigger finger and subsequently released during open
release for trigger figner is the A1 pulley.
Medscape. Flexor Tendon Anatomy: eMedicine Clinical Procedures. [Online] January 4, 2010.
[Cited: January 4, 2010.] http://emedicine.medscape.com/article/1245236-overview. (43)
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Figure 2: Normal and Pathologic Pathology of the A1 Pulley in Trigger Finger

Figure 2: Normal vs. pathological A1 pulley showing two normal layers of connective tissue in
the top panel and three layers in the pathologic pulley. The inner layer, marked c, is postulated
to be pathologic tissue.
Histopathology of the A1 pulley in adult trigger fingers. Sbernardori MC, Bandiera P. 2007, J
Hand Surg Eur , pp. 32(5):556-9. Epub 2007 Aug 7. (6)
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Figure 3: Chondroid Metaplasia in Trigger Finger

Figure 3: Chondroid Metaplasia in the pathologic A1 pulley (shown by arrows)

Histopathology of the A1 pulley in adult trigger fingers. Sbernardori MC, Bandiera P. 2007, J
Hand Surg Eur , pp. 32(5):556-9. Epub 2007 Aug 7. (6)
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Figure 4: Costs Associated with Trigger Finger Treatment

Figure 4: Costs associated with outpatient and surgical treatment in the UK. These are direct
costs including both professional and technical fees including supplies.
Cost minimisation using clinic-based treatment for common hand conditions--a prospective
economic analysis. Webb JA, Stothard J. 2009 Mar, Ann R Coll Surg Engl, pp. 91(2):135-9.
(39)

Figure 5: Decision Tree analysis for cost of trigger finger treatment strategies from Kerrigan et al. Five treatment arms are examined.
Using evidence to minimize the cost of trigger finger care. Kerrigan CL, Stanwix MG. 2009, J Hand Surg Am. , pp. 34(6):997-1005. (40).

Figure 5:
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Figure 6a: Summary of outcomes in study group. A total of 91 digits were initially enrolled and had outcomes as shown in the figure above.

Figure 6a: Outcomes of Study Group
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Figure 6b: Decision Tree Analysis for Patients with History of Injection Resistant Trigger Finger Presenting with New Trigger Digit with Four
Decision Branches. The dominant branch (i.e. the branch with the lower average costs) is marked as TRUE and probability of each outcome
marked in each branch end point (shown as a blue triangle).

Figure 6b: Decision Tree Analysis using all treatment algorthims.
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Figure 7: Chart of Outcome Probabilities

Figure 7: The bar chart shows the probability and value of each outcome in the decision tree
shown in Figure 6b.

48
Figure 8: Sensitivity Analysis of Cost of Surgery for Decision Tree Analysis.

Figure 8: The sensitivity analysis varies the cost of surgery against the cost of injection. The point
of intersection represents the cost of surgery at which surgery becomes more cost effective than
injection treatment.

Figure 9: As no other studies have established success rates for treatment protocols using three steroid injections, a separate decision tree analysis
was performed for treatment protocols using up to two steroid injections. In this decision tree, the dominant strategy was to us up to two steroid
injections as initial treatment followed by open surgery in the case of non-operative treatment failure.

Figure 9: Decision Tree Analysis with Three Decision Nodes.
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Table 1: Classification of Trigger Fingers as in Wolfe SW. Tenosynovitis. In: Green DP,
Hotchkiss R/, Pederson WC, eds. Green's operative hand surgery, 4th ed. New York: :
Churchill Livingstone, , 1999:2022–2044. (13).

TABLE 1. CLASSIFICATIO/ OF TRIGGER FI/GERS
Characteristics
Pain; positive sign of trigger finger not
evaluated during the objective medical
examination; increased sensibility toward
pain in correspondence with the first
annular pulley.
II (active)
Objective presence of trigger finger; the
patient is able to extend the finger actively.
III A (passive)
Objective presence of trigger finger.
Extension is only possible passively with
the help of an applied external force
III B
Objective presence of trigger finger.
The patient is unable to actively flex the
finger.
IV (rigidity) in a flexion posture.
Objective presence of trigger finger; the
proximal interphalanx is stuck
Grade
I (pretrigger)

RADIOGRAPHIC FINDINGS - CONTROL GROUP
Xray Findings
Number Percentage
OA
16
40%
Normal
22
55%
Other
2
5%

30%
70%
N/A
40%

Percentage

PAST MEDICAL HISTORY - STUDY GROUP
PMH
Number
Percentage
Diabetes
11
26%
Diabetes with Insulin
1
2%
Hypothyroidism
4
9%
Gout
1
2%
None of the above
24
56%

0.46
0.012

0.65

P value

0.36
0.73
0.52

P value

0.95
0.96
0.59
0.96
0.97

P value

RADIOGRAPHIC FINDINGS STUDY GROUP
Xray Findings
Number Percentage
OA
13
30%
Normal
22
51%
Other
1
2%

Table 3b: Radiographic Data for Presence of Osteoarthritis of the Hand

PAST MEDICAL HISTORY - CONTROL GROUP
PMH
Number
Percentage
Diabetes
10
25%
Diabetes with Insulin
1
3%
Hypothyroidism
6
15%
Gout
1
3%
None of the above
26
65%

Table 3: Past Medical History

35%
65%
N/A
15%

Number
43
13
30
29
17

Summary Statistics
Number of Patients
Male Patients
Female Patients
Average BMI
Occupational Exposure

Percentage

Summary Statistics
Number of Patients
Male Patients
Female Patients
Average BMI
Occupational Exposure

Number
40
14
26
29
6

DEMOGRAPHICS - STUDY GROUP

DEMOGRAPHICS - CONTROL GROUP

Table 2: Table of Demographics of Study and Control groups showing statistically significant differences in occupational exposure.
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Thumb Affected
Index Affected
Long Affected
Ring Affected
Small Affected

Number
20
2
13
12
2

Percentage
41%
4%
27%
24%
4%

TRIGGER FINGER CHARACTERISTICS - CONTROL
GROUP
Trigger Finger Characteristics
Number Percentage
Number of Trigger Fingers
49
Number of Patients
40
Right Hand Fingers Affected
28
73%
Left Hand Fingers Affected
21
53%
Dominant Hand Fingers Affected
28
73%

Thumb Affected
Index Affected
Long Affected
Ring Affected
Small Affected

Number
17
14
31
21
8

Percentage
19%
15%
34%
23%
9%

TRIGGER FINGER CHARACTERISTICS - STUDY
GROUP
Trigger Finger Characteristics
Number Percentage
Number of Trigger Fingers
91
Number of Patients
43
Right Hand Fingers Affected
49
54%
Left Hand Fingers Affected
42
46%
Dominant Hand Fingers Affected
38
42%

0.0044
0.045
0.36
0.85
0.31

P value
n/a
n/a
0.11
n/a
0.083

Table 4: Index case of trigger finger, average number of injections, time till injections, percentage that have surgery, dominant hand affection,
finger affected
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PAST HAND TREATMENT - STUDY GROUP
Treatment for Other Hand Dx
Number Percentage
Splints
13
30%
Therapy
11
26%
Injections
15
35%
NSAIDS
5
12%
Surgery
15
35%

Number Percentage
19
44%
8
19%
27
63%
2
5%
5
12%
0
0%
7
16%
4
9%
4
9%
7
16%

OTHER HAND COMORBIDITIES - STUDY GROUP

Number Percentage Other Hand Dx
6
15%
Carpal Tunnel Syndrome
3
8%
Bilateral Carpal Tunnel Syndrome
9
23%
Total Carpal Tunnel Syndrome
3
8%
Cyst
4
10%
Dequervain’s
0
0%
RSI
7
18%
Impingement
3
8%
Epicondylitis
0
0%
Dupuytren's
7
18%
Other

PAST HAND TREATMENT - CONTROL GROUP
Treatment for Other Hand Dx
Number Percentage
Splints
6
15%
Therapy
13
33%
Injections
9
23%
NSAIDS
3
8%
Surgery
12
30%

Other Hand Dx
Carpal Tunnel Syndrome
Bilateral Carpal Tunnel Syndrome
Total Carpal Tunnel Syndrome
Cyst
Dequervains
RSI
Impingement
Epicondylitis
Dupuytren's
Other

OTHER HAND COMORBIDITIES - CONTROL GROUP

Table 5: Other upper extremity conditions, treatment for other upper extremity conditions

0.1
0.49
0.22
0.53
0.64

0.0034
0.14
0.0001
0.59
0.81
1.00
0.88
0.77
0.026
0.88

P value

53

54
Table 6a: Duration of Symptoms before first injection and before surgery for the control group
CONTROL
All Patients

Weeks

Time from Onset of Symptoms
to First Injection

16.06

Time from Onset of Symptoms
to Surgery

N/A

Patients that had Surgery

Weeks

Patients that did not have
Surgery

Weeks

P value

Time from Onset of Symptoms
to First Injection

15.45

Time from Onset of
Symptoms to First Injection

16.08

0.94

Time from Onset of Symptoms
to Surgery

58.06

Time from Onset of
Symptoms to Surgery

N/A
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Table 6b: Duration of Symptoms before first injection and before surgery for the study group
STUDY GROUP
All Patients

Weeks

Time from Onset of Symptoms
to First Injection

14.11

Time from Onset of Symptoms
to Surgery

N/A

Patients that had Surgery

Weeks

Patients that did not have
Surgery

Weeks

Time from Onset of Symptoms
to First Injection

15.20

Time from Onset of
Symptoms to First Injection

12.93

Time from Onset of Symptoms
to Surgery

101.74

Time from Onset of
Symptoms to Surgery

N/A

P value
0.56
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Table 6c: Duration of Symptoms before first injection and before surgery of study vs control
group
CONTROL
All Patients

Weeks

STUDY GROUP
All Patients

Weeks

Time from Onset of Symptoms
to First Injection

15.91

Time from Onset of
Symptoms to First Injection

14.11

Time from Onset of Symptoms
to Surgery

N/A

Time from Onset of
Symptoms to Surgery

N/A

Patients that had Surgery

Weeks

Patients that had Surgery

Time from Onset of Symptoms
to First Injection

15.45

Time from Onset of
Symptoms to First Injection

Time from Onset of Symptoms
to Surgery

58.06

Patients that did not have
Surgery

P Value

0.64

Weeks
15.2

0.97

Time from Onset of
Symptoms to Surgery

101.74

0.073

Weeks

Patients that did not have
Surgery

Weeks

Time from Onset of Symptoms
to First Injection

16.08

Time from Onset of
Symptoms to First Injection

12.93

Time from Onset of Symptoms
to Surgery

N/A

Time from Onset of
Symptoms to Surgery

N/A

0.55
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Table 7: Surgery prevalence among the control and study groups

Total Patients
Number of Patients + Surgery
Number of Patients - Surgery
Total Digits
Number of Digits + Surgery
Number of Digits - Surgery

Control
40
9
31
49
11
38

Percentage
23%
78%
22%
78%

Study
43
21
22
91
35
56

Percentage

P value

49%
51%

0.01
-

38%
62%

0.05

72%
22%
78%

23
11
28

80%
80%
28%

Percent

Number
40
32
49
39
9

Of Digits That Did Not have Surgery (28 Digits in 23 Patients)
Number With No Symptoms
16
57%
Number With Pain
3
9.6%
Number With Stiffness
9
32%
Number With Clicking/Locking
0
0%
Number Satisfied With Injection
Treatment
22
79%
Number Who Would have
Injection Treatment Again
24
86%
Patients Satisfied With Injection
Treatment
21
91%
Patients Who Would have
Injection Treatment Again
21
91%

Control Group
Number of Patients
Number Surveyed
Total Digits
Digits Surveyed
Patients Surveyed Who Had Surgery
Patients Surveyed Who Did Not Have
Surgery
Digits Surveyed That Had Surgery
Digits Surveyed That Did Not Have
Surgery

Table 8: Survey Data

Patients Satisfied With Injection Treatment
Patients Who Would have Injection
Treatment Again

Digits Satisfied With Injection Treatment
Digits Who Would have Injection
Treatment Again

83%
83%

10

97%

29
10

97%

29

87%
10%
0%
0%

Of Digits That Did Not have Surgery (30 Digits in 11
Patients)
Number With No Symptoms
26
Number With Pain
3
Number With Stiffness
0
Number With Clicking/Locking
0

50%
45%

60%
50%

56%

Percent

55%

12
25

Number
43
24
91
55
12

30

Digits Surveyed That Did Not Have Surgery

Study Group
Number of Patients
Number Surveyed
Total Digits
Digits Surveyed
Patients Surveyed Who Had Surgery
Patients Surveyed Who Did Not Have
Surgery
Digits Surveyed That Had Surgery

0.5

0.5

0.14

0.035

0.011
0.93
0.0005
1

0.13

0.098
0.13

0.0004
0.098

0.019

P value
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Table 9: Diabetes

Control Diabetes +
Control Diabetes Study Group Diabetes +
Study Group Diabetes -

Surgery
1
8
5
16

No
Surgery
7
24
6
17

0.44

0.63

P value

Percentage
13%
25%
54%
48%

P value
0.3
0.94

Table 10: Multiple Presenting Fingers vs Single Presenting Fingers:

Cont Multiple Finger Presentation
Cont Single Finger Presentation
Study Multiple Finger Presentation
Study Single Finger Presentation
P value

Surgery
0
9
2
19

No
Surgery
3
28
2
20

0.36

0.15

Percentage
0%
24%
50%
49%

P value
0.34
0.96
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Form 1: Consent Script and Survey Data Collection Sheet
Hello this is ________________. I am contacting you because you are a potential volunteer in a
study being conducted by Dr. Bernstein’s office at The Orthopaedics Group, LLC. We are
conducting a survey on your experience with injection treatment for trigger finger studying how
effective injections were in treating your symptoms. This study takes about 10 minutes and you
are under no obligation to participate. If you have any questions at anytime during this survey, do
not hesitate to ask. Your participation in this survey will in no way affect your relationship with
The Orthopaedics Group, LLC. The information obtained in this survey such as your name and
symptoms and treatment for trigger finger will be used in conjunction with your information from
you medical records like your past medical history relevant to trigger finger and symptoms and
treatment of trigger finger and later de-indentified. This information will be protected by securely
storing the information in password protected documents on password protected computers, with
monthly security reviews. Do you consent to participate in this survey and for the use of your
protected health information as described for this study?

Subject Name:____________________________Date of Survey:_________________________
Consent Given:___________________________Date of Consent:________________________
Consent Obtained by:______________________
Hand Affected: Right

Left

Finger Affected: T

Are you having pain in the previously injected finger?
If yes then rate pain:

0

1

2

3

4

5

6

Yes
7

8

I

L

R

S

No
9

10 (10=max, intolerable)

Are you experiencing any stiffness in the previously injected finger?

Significant Mild

Are you experiencing any clicking/locking in the finger?

None

Have you received treatment anywhere else for the previously injected finger?

Rare
Yes

None

Constant
No

If yes What was done? Surgery Therapy Injection Other______________________________
Did you have surgery on the trigger finger?
If no to the surgery question
Were you satisfied with the injection treatment for the trigger finger?
Would you have the injection treatment again if needed?

Yes

Yes

No
No

